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Abstract
Background: HIV-1 subtype C demonstrates several biological properties distinct from other viral subtypes. One
such variation is the duplication of PTAP motif in p6 Gag. PTAP motif is a key player in viral budding. Here, we
studied the prevalence of PTAP motif duplication in subtype C viral strains in a longitudinal study.
Methods: In a prospective follow-up study, 65 HIV-1 seropositive drug-naive subjects were monitored in two different
clinical cohorts of India for 2 years with repeated sampling at 6-month intervals. The viral RNA was extracted from
plasma, the gag segment was amplified and sequenced. From a subset of viral isolates the sequences of pol, env and
LTR were sequenced. Using HIV-1 gag amino acid sequences available from public databases and additional sequences
derived from the Indian and South-African cohorts, we examined the nature of PTAP motif duplication in subtype C.
Results: In 16% (8 of 50) of the primary viral strains of India, we identified a sequence duplication of the PTAP motif in
Gag p6. The length of the sequence duplication varied from 6 to 14 amino acids in the viral isolates but remained fixed
within a subject over a period of 24–36 month follow-up. In the duplicated motif, the core PTAP motif was invariable,
but the flanking residues were highly variable. In an acute phase clinical cohort of South Africa, in a subset of 75
subjects, we found the presence of the PTAP duplication at a frequency of 29.3%. An analysis of the gag sequences
from the extant databases showed that unlike other subtypes of HIV-1, subtype C has a natural propensity to generate
the PTAP motif duplication at a significantly higher frequency and of greater length. Additionally, the global prevalence
of PTAP duplication in subtype C appears to be increasing progressively over the past 30 years.
Conclusion: We showed that in subtype C, the duplication of the PTAP motif in p6 Gag involves sequence stretches of
greater length, and at a much higher frequency as compared to other HIV-1 subtypes. Given that subtype C naturally
lacks the Alix binding motif, the acquisition of an additional PTAP motif may confer replication advantage on this HIV-1
subtype. Further investigation is warranted to examine the significance of PTAP motif duplication on the replicative
fitness of HIV-1.
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Background
HIV-1 subtype C is responsible for approximately half of
all global infections [1]. HIV-1 subtypes differ from each
other in genetic sequence, geographical distribution,
co-receptor usage, pathogenic potential, and replication
and transmission properties [2, 3]. It is increasingly
appreciated that the subtype-unique genetic variations
may have a significant impact on the viral biological
properties that in turn may influence the differences in
the prevalence of the viral subtypes and pathogenesis.
HIV-1 subtype C appears to have a unique potential to
introduce sequence duplications at specific locations in
the viral genome at a much higher frequency than the
other HIV-1 subtypes. Importantly, the sequence inser-
tions in subtype C are significantly longer permitting the
acquisition of additional copies of biologically functional
motifs, by the duplication of the adjacent sequences.
This phenomenon is expected to enhance the replication
fitness of the variant viral strains. For example, the du-
plication of a 21 bp sequence motif in the viral promoter
was shown to create a fourth NF-κB motif (typically, the
canonical subtype C promoter contains three NF-κB
binding sites) in the Long terminal repeat (LTR) [4]. We
recently demonstrated that the 4-κB viral strains have
been spreading in the population at a rapid rate in India
dominating the 3-κB viruses [5].
The second case of sequence duplication creating an
additional functional motif of biological significance is
evident in the PTAP motif (the motif consisting of the
four Proline, Threonine, Alanine, and Proline amino
acids) of Gag p6, a 52 amino-acid protein [6–8]. HIV-1
gag varies genetically up to 8–19% among the diverse
viral subtypes [9–11] and possesses subtype-specific
genetic variations [12, 13]. The p6 domain of Gag is
highly flexible and can accommodate a wide range of
length variations due to sequence insertion or dele-
tion that possibly modulates Gag functions [14, 15].
Numerous insertions and deletions have been re-
ported in Gag p6 of which the most common inser-
tions are in the PTAP, KQE and FRFG motifs of
subtype B [16] and subtype C [17]. The polyfunc-
tional Gag p6 is associated with the recruitment of
several host factors required for the viral particle for-
mation. The PTAP motif located in the L-domain of
p6 recruits the primary budding factor tumor suscep-
tibility gene 101 (Tsg101) and the other components
of the endosomal sorting complex (ESCRT) machin-
ery to the site of virus assembly [18]. Additionally, a
second domain, the YPXnL motif, binds ALG-2 inter-
acting protein 1/X (ALIX) [19] which is believed to
enhance the viral budding (Fig. 1a). Thus, Gag p6
plays a critical role in viral budding especially via an
interaction with the Tsg101 and the ESCRT machin-
ery using the PTAP motif.
Importantly, several studies previously reported the
accumulation of sequence insertions at the N-terminal
region within the PTAP motif of Gag p6 [8, 20–22]. The
sequence duplication at this location may be divided into
two categories based on whether or not the core PTAP
motif is duplicated. Based on this classification, most of
the sequence insertions reported in the primary clinical
isolates of subtype B are characterized by only a partial
sequence duplication that does not lead to the creation
of an additional PTAP motif but only a part of the motif.
In subtype B, while a large number of the sequence in-
sertions duplicated a three amino acid stretch ‘APP’ in
Gag p6 and ‘SPT’ in Gag-Pol p6 (Fig. 1b), only a small
fraction of the sequence insertions constituted a
complete duplication of the PTAP motif. Of note, the
DNA sequence encoding Gag p6 is also translated in a
different reading frame, following a frame-shift, to en-
code a different protein called Gag-Pol transframe do-
main p6* or Gag-Pol p6 of 56 amino acids. The
sequence variations in this region of the virus, therefore,
are likely to influence two different viral protein deriva-
tives Gag p6 and Gag-Pol p6.
The administration of the antiretroviral therapy (ART)
appears to have a significant impact on the nature and
frequency of the amino acid sequence insertion in the
PTAP motif although the significance of this observation
to drug resistance is not known [23]. A positive correlation
was identified between nucleoside-based ART and PTAP
duplication in HIV-1 subtype B infection [7, 24–26].
Furthermore, amino-acid polymorphism in Gag p6
can affect viral replication [27] with an increase in
infectivity and resistance to reverse transcriptase (RT)
inhibitors [16, 27]. A significant increase in the
prevalence of the PTAP motif sequence insertion fol-
lowing ART exposure in subtypes B (p = 0.0294) and
C (p = 0.0001) alludes to a potential role of the dupli-
cation in antiretroviral drug-resistance [28]. The pro-
posed association between ART treatment and the
PTAP duplication, however, is controversial based on
two other observations. First, some studies failed to
find a significant difference in the frequency of the
PTAP insertion between ART-naïve and ART-exposed
arms in subtype B [29]. Second, the high frequency of
the PTAP sequence duplication in drug-naive subjects
of subtype C alludes to a different role for the
sequence insertion other than drug resistance [28].
The biological significance of the PTAP motif se-
quence duplication, predominantly partial in subtypes B
and others (mostly an insertion of three amino acid
sequence) and complete in subtype C (sequence inser-
tions of four amino acids or longer, mostly as long as 14
amino acids) has not been evaluated adequately. In this
backdrop, a publication from Brazil examined PTAP
duplication in a clinical cohort of drug-naïve and
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drug-experienced arms representing HIV-1 infection
of three different subtypes B, C and F [28]. This
study identified a significant elevation in the fre-
quency of PTAP duplication in subtype C as com-
pared to the other two subtypes in both the arms of
the study. In the backdrop of the paucity of studies
examining the higher and importantly, longer se-
quence duplication of the Gag p6 PTAP motif in sub-
type C, the primary objective of the present work is
to evaluate the prevalence of the PTAP duplication in
the primary infections of HIV-1 subtype C in India.
In a longitudinal follow-up of 2 to 3 years (2010–
2013) of two different cohorts of southern India con-
sisting of 65 HIV-1 seropositive subjects, we ascertain
the higher frequency of the PTAP motif duplication
in subtype C. Additionally and importantly, we dem-
onstrate that the length of the PTAP duplication in




Ethical approval for the present study was granted by
the Institutional Review Board of YRG CARE (Y. R.
Gaitonde Centre for AIDS Research and Education),
Chennai. A written informed consent was obtained from
all the subjects enrolled in the study and maintained
with confidence. The Human Ethics and Biosafety
Committee of JNCASR (Jawaharlal Nehru Centre for
Advanced Scientific Research), Bangalore reviewed the
proposal and approved the study.
Characteristics of the study and the clinical samples
From the clinical records available at YRG CARE over
the past several years, seropositive subjects were en-
rolled in two different clinical cohorts, called the YRG
CARE (Chennai, Tamil Nadu) and Nellore (Andhra
Pradesh) cohorts, for the longitudinal study spanning
over a period of 2–3 years. 30 subjects belonged to YRG
CARE cohort, Chennai, Tamil Nadu and 35 subjects to
the Nellore cohort, Andhra Pradesh. The participants of
the YRG CARE cohort were diagnosed between years
1996 and 2008, and the dates of diagnosis of the Nellore
cohort are not available. The clinical samples were col-
lected at an interval of 6 months. The primary inclusion
criteria consisted that the CD4 counts should be above
500 cells/μl at the time of enrollment and that the
subjects should be drug-naive and free of AIDS-related
clinical symptoms. The exclusion criteria included the
presence of opportunistic infections, signs of acute
Fig. 1 a Schematic representation of HIV-1 Gag protein domains. The four major domains of Gag (MA, CA, p7, and p6) are depicted including the
two linker sequences p1 and p2. HIV-1 Gag interacts with the ESCRT complex proteins Tsg101 and Alix to regulate viral budding. The sequence
of subtype B NL4-3 gag p6is presented and the sequence motifs PTAP and YPXnL, which serve as the binding motif for Tsg101 and Alix, respectively,
are highlighted using the square boxes. Con_C represents the subtype C gag p6 consensus amino acid sequence. The dashes represent sequence
identity and the dots sequence deletion. b A comparative analysis of the PTAP sequence duplication in subtypes B and C. In subtype B, a partial PTAP
duplication consisting of three amino-acid residues (APP) is common. In contrast in subtype C, a sequence duplication of 14 amino acids is common.
A 14 amino acid sequence duplication of subtype C derived from the primary clinical isolate T004 is presented. The amino acid sequences, the original
and the duplicated sequences, in Gag and Gag-Pol are depicted. The arrows represent the length of sequence duplication and the direction of
polymerization by the reverse transcriptase while synthesizing the cDNA from the viral RNA. The core PTAP motifs are highlighted using the square
boxes. The sequences flanking the 3 or 14 aa residues are shown in gray
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systemic illness and prior antiretroviral treatment. The
study participants consisted of only adult subjects over
18 years of age. The subjects were all drug-naive and be-
lieved to have acquired the infection primarily through
heterosexual transmission. The clinical profile of the
subjects including the subject ID, sampling date, age,
gender, viral load and CD4 count has been summarized
(Table 1).
The clinical procedures
A single vial of 20 ml of peripheral blood was collected
from each participant at 6-month intervals during
2010–13. The blood samples were collected in EDTA
vacutainers (Becton Dickinson, San Diego, USA) and
were processed on the same day of collection. The
PBMC and plasma samples were stored in 1 ml aliquots
in a liquid nitrogen container and a deep freezer, re-
spectively. Genomic DNA extracted from 200 μl of
whole blood using a commercial DNA extraction kit
(QIAmp Blood Mini Kit, Cat. No: 69504, Qiagen India,
New Delhi, India). The CD4 T-cell count was deter-
mined using the BD FACSCount Reagent Kit (Cat. No:
340167, Becton Dickinson, San Jose, California, USA)
and the BD FACSCount Control Kit (Cat. No: 340166)
following the manufacturer’s instructions. The samples
were analyzed on a BD FACS Calibur flow cytometer.
The plasma viral RNA load was determined using the
Abbott m2000rt Real-Time PCR machine (Abbott
Molecular Inc. Des Plaines, IL, USA). All the methods
were carried out in accordance with Institutional Ethics
Committee for Human Research guidelines of the Indian
Council for Medical Research (ICMR), New Delhi.
RNA isolation and RT-PCR
RNA was extracted from 150 μl of plasma samples using
a commercial Viral RNA isolation kit (NucleoSpin® RNA
Virus, Ref. No. 740956.50, MACHEREY-NAGEL GmbH
& Co. KG, Germany). In the case of the clinical samples
that failed the PCR, an alternative kit was used to extract
the viral RNA from 1 ml of plasma (the NucliSENS
miniMAG nucleic acid extraction kit, Ref. No. 200293,
BioMerieux, France). The complementary DNA (cDNA)
was synthesized using random hexamers and a commer-
cial kit (SuperScript® III Reverse Transcriptase, Cat. No:
18080–051, Invitrogen, Carlsbad, California, USA). The
reaction vials were incubated at 25 °C for 10 min and
50 °C for 50 min. The reactions were terminated at 85 °C
for 5 min followed by RNaseH treatment. The cDNA
was used for the amplification of Gag and other viral
gene segments.
Amplification of Gag and the DNA sequencing
The full-length gag was amplified from the cDNA using
a nested-PCR strategy and a commercial long-range
PCR kit (XT-20 PCR system, Merck Genie, India) on the
I-Cycler (Bio-Rad, California, USA). Furthermore, from
a select subset of the participants, Gag p6, LTR,
Protease, RT, RNaseH, Integrase and Env regions were
also amplified. The details of the amplification and se-
quencing primers are summarized for gag in Table 2 and
the rest of the gene segments in Table 3. The sequence
of the V3-V5 envelope region (0.7 kb fragment,
7001–7667, HXB2 coordinates) of a few select subjects
was determined using the HIV-1 Env Subtyping Kit (The
NIH AIDS Research & Reference Reagent Program,
Germantown, MD, USA).
The reaction conditions for the Gag amplification in
both the rounds of the nested PCR were 94 °C for 2 min
for one cycle and then 35 cycles, each cycle consisting of
melting at 94 °C for 30 s, annealing at 50 °C for 50 s,
and extension at 72 °C for 2 min, followed by final ex-
tension at 72 °C for 5 min. Two μl of the first-round
PCR products were transferred to the second-round
PCR to amplify the complete gag sequence. The details
of the primers and the amplified products are summa-
rized in Table 2. Carryover contamination was prevented
by adherence to strict procedural and physical safe-
guards that included reagent preparation and PCR setup,
amplification, and post-PCR processing of samples in
separate rooms. The PCR products were purified using a
commercial DNA purification kit (Cat. No. YDF100, Real
Biotech Corporation, Taiwan) and subjected to sequen-
cing. The sequencing was performed on ABI PRISM®
3130xl Genetic Analyser (Applied Biosystems, Illinois,
USA) using multiple internal sequencing primers. The se-
quences are available from GenBank under the accession
numbers KF578465-KF578467, KT124420-KT124478, KT
152633-KT152672, and KP890700-KP890762.
Phylogenetic and sequence analyses
Phylogenetic analysis was performed using the reference
sequences of HIV-1 group M available from the Los
Alamos database (http://www.hiv.lanl.gov/). Sequences
were manually edited using Bio-Edit software version
7.0.5.3. Multiple sequence alignments were performed
using ClustalW in the BioEdit software (version 7.0.5.3).
The phylogenetic tree was constructed using the
neighbor-joining method (Kimura two-parameter model)
in 1,000 bootstrapped data sets, using the Molecular
Evolutionary Genetics Analysis (MEGA) software ver-
sion 5 [30]. The evolutionary distances were computed
using the Maximum Composite Likelihood method and
are in the units of the number of base substitutions per
site. All the positions containing gaps and missing data
were eliminated. The final dataset contained a total of
1,632 nucleic acid positions. Additionally, genetic sub-
type characterization of the gag sequences was per-
formed using the REGA HIV-1 Subtyping Tool version
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Table 1 The clinical profile of the study subjects belonging to two different clinical cohorts of India
(A) The YRG CARE cohort, n = 30






Time (months from the date of enrolment) GenBank Accn. No.
PVL CD4 CD8
M0 M12 M24 M0 M6 M12 M18 M24 M30 M0 M12 M24 gag
T-001 22–05–2002 26–11–2010 28/F 12074 29617 60953 560 569 525 530 645 355 1633 1804 1273 KT152633
T-002 22–01–2002 06–12–2010 34/F 15354 16293 6852 517 855 740 879 565 584 610 762 734 KP890700–11
T-004 15–03–2004 16–12–2010 29/F 33784 36627 112577 553 442 508 359 321 296 >2000 >2000 1910 KT152674–686
T-005 13–12–2003 20–12–2010 26/F 912 x x 770 x x x x x >2000 x x KT152634
T-006 25–08–2008 29–12–2010 28/F 1638 24773 x 527 480 409 547 x x 1513 1199 x KP890712–21
T-007 27–10–2007 30–12–2010 26/F <150 263 722 958 799 1016 886 1311 x 859 992 1380
T-008 17–10–2008 20–01–2011 30/F 34640 172183 x 468 480 484 432 476 415 1158 1083 901 KP890722-38
T-009 24–08–2006 24–01–2011 27/F 14672 76956 24797 695 x 603 x 330 x 1927 1930 928 KP890739-45
T-010 22–02–1996 29–01–2011 39/F <150 <150 <150 641 785 813 NA 525 x 880 1105 679
T-011 14–10–2004 29–01–2011 42/F 45583 7780 107965 823 559 489 533 575 x 1071 1191 1043 KP890746–61
T-012 20–09–2008 03–02–2011 30/F <150 <150 x 1380 NA 1549 1964 x x 1142 1071 x
T-013 20–04–2005 02–12–2011 25/F 438 3877 4528 856 580 816 718 502 724 1214 1424 1164 KT152635–37
T-014 28–10–2002 16–02–2011 35/F 2888 4578 x 553 484 376 436 425 x 1000 743 973 KT152638–42
T-015 11–05–2002 25–02–2011 36/F 542 3120 x 920 1000 820 880 830 x 1237 1097 1321 KT152643–47
T-016 22–10–2007 09–08–2011 38/F 1664 1401 x 730 x 653 x x x 1535 1366 x KT152648–49
T-017 20–12–2006 27–09–2011 36/F 5598 x x 504 332 325 x x x 2000 >2000 x KT152650–52
T-018 16–03–2007 29–08–2011 34/M 6645 x 150244 519 563 483 452 446 x 1751 1732 1283 KT152653–56
T-019 31–05–2007 19–09–2011 39/M 63722 x x 238 x x x x x 1379 x x KT152658
T-020 03–12–2008 11–12–2011 35/M <150 489 x 459 x x x x x >2000 x x KT152659
T-021 14–06–2008 14–10–2011 52/M 31410 x x 676 651 641 x x x 884 861 x
T-022 20–07–2007 19–12–2011 38/M 6625 46553 x 624 522 558 488 x x >2000 >2000 x KT152660–63
T-023 12–08–2004 23–02–2012 39/F <150 x x 987 x x x x x 1195 x x
T-024 19–02–2007 28–02–2012 50/F 541 x x 914 1179 1570 1574 x x 1174 >2000 x KT152664
T-025 11–06–2007 07–03–2012 38/F 1294 4369 x 789 950 693 x x x 1724 1968 x KT152665
T-026 11–07–2007 15–03–2012 54/F 197 <150 974 907 x 1215 x 922 x 1345 1517 1748
T-027 29–04–2005 26–03–2012 36/F <150 x x 1195 630 x x x x 767 x x
T-028 25–05–2007 19–04–2012 28/F 162112 x x 398 318 x x x x 885 x x KT152666-68
T-029 31–12–2007 28–04–2012 30/F 1659 1504 x 618 694 599 545 x x 1362 x x KT152669-70
T-030 22–12–2005 03–05–2012 42/F 284879 1E + 06 x 545 410 368 x x x 1352 x x KT152672-73














Table 1 The clinical profile of the study subjects belonging to two different clinical cohorts of India (Continued)
(B) The Nellore cohort, n = 35
Subject-ID Enrolment date Age/ Gender Cell count PVL GenBank Accession No.
CD4 CD8 Gag
INDO-SA-NLR2001 26–09–2011 23/F 608 1035 25149
INDO-SA-NLR2002 26–09–2011 32/F 589 927 26186 KT124420–21
INDO-SA-NLR2003 26–09–2011 69/M 1140 1192 548 KT124422
INDO-SA-NLR2004 26–09–2011 43/F 1012 1240 6070 KT124423–24
INDO-SA-NLR2005 26–09–2011 35/F 599 773 5713 KT124425–27
INDO-SA-NLR2006 26–09–2011 46/F 659 1185 662 KT124428
INDO-SA-NLR2007 26–09–2011 40/M 546 912 11986 KT124429–31
INDO-SA-NLR2008 26–09–2011 46/M 1289 1175 3687 KT124432–33
INDO-SA-NLR2010 26–09–2011 32/F 989 1497 251 KT124434–36
INDO-SA-NLR2011 26–09–2011 28/F 582 642 2704 KT124437
INDO-SA-NLR2012 28–09–2011 28/F 1087 1420 6070 KT124438–39
INDO-SA-NLR2014 28–09–2011 55/M 766 >2000 88645 KT124440–41
INDO-SA-NLR2015 28–09–2011 34/F 1019 >2000 21108 KT124442–43
INDO-SA-NLR2016 28–09–2011 29/F 631 1465 26363 KT124444–46
INDO-SA-NLR2017 28–09–2011 39/M 581 1050 8972 KT124447–49
INDO-SA-NLR2018 28–09–2011 35/F 825 1637 6493 KT124450–52
INDO-SA-NLR2019 28–09–2011 35/F 1085 1078 185 KT124453
INDO-SA-NLR2020 28–09–2011 38/M 570 1268 70025 KT124454–56
INDO-SA-NLR2022 28–09–2011 38/M 1489 1470 <150 KT124457
INDO-SA-NLR2023 28–09–2011 28/M 8.2 >2000 <150
INDO-SA-NLR2024 14–10–2011 30/F 984 1279 340
INDO-SA-NLR2025 14–10–2011 30/M 500 825 3423 KT124458–60
INDO-SA-NLR2026 14–10–2011 18/M 1015 1546 8733 KT124461–63
INDO-SA-NLR2028 14–10–2011 34/F 711 1409 24480 KT124464–65
INDO-SA-NLR2029 14–10–2011 35/F 1148 1290 <150
INDO-SA-NLR2030 14–10–2011 39/F 1185 1041 <150
INDO-SA-NLR2031 14–10–2011 50/F 1007 498 <150
INDO-SA-NLR2032 14–10–2011 45/M 671 821 9468 KT124466–68
INDO-SA-NLR2036 14–10–2011 27/M 860 1715 3332 KT124469–70














Table 1 The clinical profile of the study subjects belonging to two different clinical cohorts of India (Continued)
INDO-SA-NLR2038 31–10–2011 33/M 669 777 26542 KT124473
INDO-SA-NLR2039 31–10–2011 47/M 925 1111 4563295 KT124474–75
INDO-SA-NLR2040 31–10–2011 29/M 1181 978 <150
INDO-SA-NLR2041 31–10–2011 45/M 888 1237 56445 KT124476–77
INDO-SA-NLR2042 02–12–2011 26/F 1280 >2000 4797 KT124478
Note: Accession Numbers. KP890700-KP890762 and KT152677-686: Full-length gag sequences of six subjects (T002, T004, T006, T008, T009 and T011) at M0 time-point as determined using the plasmid clone
sequencing strategy. The rest of the sequences were determined by direct sequencing of the PCR amplicons of the same subjects at the follow-up time-points
M: The month of sample collection at 6 month interval from baseline M0
X: Information not available
−: Failed PCR amplification
PVL: Plasma viral load (number of RNA copies/ml)














2.0, available at the BioAfrica site (http://www.bioafrica.
net/rega-genotype/html/) and the recombinant identifi-
cation tool available at the Los Alamos HIV Sequence
Database (http://hiv.lanl.gov/content/index). Every indi-
vidual gene sequence was subjected to a BLAST ana-
lysis against the laboratory sequence database to
confirm authenticity. All the other HIV-1 gag sequences
required for the analysis were retrieved from the Los
Alamos HIV Sequence Database (http://hiv.lanl.gov/con-
tent/index).
To evaluate the global prevalence of the PTAP
duplication, the Los Alamos National Laboratory
(LANL) HIV sequence database was searched for glo-
bal HIV-1 gag sequences for subtype A, B, C, D, F, G,
CRF01_AE, CRF02_AG and CRF07/08_BC as of Octo-
ber 2015. Of note, the partial sequence insertions not
duplicating the core PTAP motif or amino acid inser-
tions not related to PTAP were not included in the
analysis. In silico analysis was performed to under-
stand the prevalence of PTAP duplication. Further, to
evaluate the profile of PTAP duplication over the past
30 years, subtype B and C sequences were down-
loaded from the LANL sequence database excluding
the problematic sequences and acquiring one se-
quence per patient. Of note, for many sequences, the
information regarding the date of isolation of the
clinical sample was not available from the database.
We, therefore, considered the date of sequence
Table 2 Primers for Gag amplification and sequencing
Amplification primers
Primer Number Description Co-ordinates (HXB2) /Length Sequence (5'–3') Product length
Set I
N420 EFP 683–709, 27 CTCTCGACGCAGGACTCGGCTTGCTGA 1712
N1476 ERP 2366–2395, 29 CTATCATTTTTGGTTTCCATYTTCCTGGC
N1356 IFP 790–806, 27 AAGGAGACATATGGGTGCGAGAGCGTC 1516
N1435 IRP 2274–2306, 30 ATTTGGCCCCCTCGAGTTGAGACAAGRGGTCG
Set II
N420 EFP 683–709, 27 CTCTCGACGCAGGACTCGGCTTGCTGA 1832
N1634 ERP 2484–2515, 32 TTTCTTCCAATTATGTTGAYAGGTGTRGGTCC
N1632 IFP 777–806, 30 TAGAAGGCTCGAGATGGGTGCGAGAGCGTC 1666
N1633 IRP 2413–2443, 32 ATRRGTATTTGATCATAYTGTCTTACTTTGAT
Set III
N1788 EFP 577–604, 29 GACTCTGGTAACTAGAGATCCCTCAGAC 2315
N1789 ERP 2862–2892, 35 ATGCATCA/CCCCACATCCAGTACTGTYACTG
N1786 IFP 625–647, 28 ATCTCTAGCAGTGGCGCCCGAACAGGGAC 2211
N1787 IRP 2801–2836, 30 TGTGGAATTCCTAATTGRACYTCCCARAATCTG
Set IV- p6 Gag
N2301 EFP 1752–1778, 27 GTTGGTCCAAAATGCGAACCCAGATTG 1090
N2302 ERP 2813–2842, 29 GGGCCATCCATTCCTGGCTTTAATTTTAC
N2304 IFP 1859–1885, 27 GCCACAAAGCAAGAGTGTTGGCTGAGG 549
N2305 IRP 2382–2408, 27 ACCTCCAATTCCTCCTATCATTTTTGG
Sequencing primers
N1619 Forward Primers 1040–1056, 17 GGCCATTGACAGAAGA
N1620 1609–1626, 18 TTGTATGTAGGATCTGA
N1621 2092–2107, 16 TGCCCACACTAATGATG
N1812 2035–2058, 25 TGTGGAAAGGAAGGACACCAAATG
N1489 1302–1326, 25 TGTTTACAGCATTATCAGAAGGAGC
N1622 Reverse primers 1835–1818, 18 GCTGTCATCATYTCTTCT
N1623 1329–1313, 17 GGTGGCTCCTTCTGATA
N1624 910–895, 16 GCTCCCTGCTTGCCCA
N1490 1826–1849, 24 CACTCCCTGACATGCTGTCATCAT
EFP- External forward primer, ERP-External reverse primer, IRP- Internal reverse primer, IFP-Internal forward primer, Reverse primers have been presented as reverse complement
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submission instead for the analysis. It should be
noted that there could be a significant delay between
the actual date of sample collection and sequence
submission. Amino acid sequences downloaded in the
FASTA format were categorized into five groups
representing five time periods, beginning with the
year of the first sequence deposited till 2015. The re-
gression analysis was performed using GraphPad
Prism version 5.02 to examine the trend of PTAP
motif duplication over the period of past 30 years.
Results
PTAP duplications of longer sequence length are inserted
at a higher frequency in subtype C
In the present manuscript, we refer to all the viral
strains that contain a complete PTAP motif duplication
in Gag p6 as the double-PTAP strains and those that
lack such duplication as the single-PTAP strains. The
double-PTAP strains must contain a second and intact
PTAP motif comprising of the four core amino acids
with or without the additional flanking amino acids. To
Table 3 Primers for Pol and LTR amplification and sequencing
Amplification primers
Primer Number Description Co-ordinates (HXB2) /Length Sequence (5'–3') Product length
Protease
N1636 EFP 1978–2006, 29 AAGGAAGGGCACCCAGCCAGAAATTGCAG 864
N1637 ERP 2813–2842, 30 GCGGGATGTGGTATCCCTAATTGAACTTCC
N1638 IFP 2075–2103, 29 GACAGGCTAATTTTTTAGGGAARATTTGG 530
N1639 IRP 2577–2605, 29 GGGCCATCCATTCCTGGCTTTAATTTTAC
RT
N1641 EFP 2368–2395, 28 CAGGAAGATGGAAACCAAAAATGATAGG 2114
N1642 ERP 4455–4482, 28 CTATATATCCACTGGCTACATGAACTGC
N1643 IFP 2489–2509, 21 TACACCTGTCAACATAATTGG 1816
N1644 IRP 4285–4305, 21 AATCACTAGCCATTGCTCTCC
RNaseH/Integrase
N2244 EFP 3628–3660, 33 CCCACACTAATGATGTAAAACAGTTAACAGAGG 1659
N2245 ERP 5257–5287, 31 CCATGACCCAAATGCCAATCTCTTTCTCCTG
N2246 IFP 3738–3765, 28 ATGGGAAACATGGTGGACAGACTATTGG 1476
N2247 IRP 5185–5214, 30 TGGGATGTGTACTTCTGAACTTAYTTTTGG
LTR
N698 EFP 1–34, 34 TGGAAGGGTTAATTTACTCYMAGAAAAGRCAAGA 555
N1032 ERP 538–556, 19 TAGAGCACGCAAGGCAAGC
N558 IFP 1–43, 43 TGGAAGGGTTAATTTACTCTAAGGAAAGGCAAGA
GATCCTTG
431
N1204 IRP 411–432, 21 CTTATATGCAGGATCTGAGGG
Sequencing primers gene
N1645 Forward Primers 2620–2635, 16 GGCCATTGACAGAAGA RT
N1646 3108–3124, 17 TTGTATGTAGGATCTGA
N1647 3626–3642, 17 TGCCCACACTAATGATG
N1648 Reverse primers 3870–3886, 17 GCTGCCCCATCTACATA
N1649 3345–3362, 18 GTAAATCTGACTTGCCCA
N1650 2889–2906, 18 GGGAACTGAAAAATATGC
9 M Forward Primers 4145–4167, 21 CCTGTCATGGGTACCAGCACA RNaseH/Integrase
10 M 4664–4687, 24 CCAAAGTCAGGGAGTAGTAGAATC
28 M Reverse primers 4957–4978, 22 ACTACTGCCCCTTCACCTTTCC
29 M 4380–4401, 22 GACTGCAGTCTACTTGTCCATG
Protease and LTR were sequenced using amplification primers
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examine the nature of the PTAP sequence insertion in
HIV-1 Gag p6 in different HIV-1 genetic subtypes, we
analyzed a total of 17,769 full-length HIV-1 Gag se-
quences available from the Database. Eleven percent of
the sequences (1,997) contained insertions that consti-
tuted the duplication of the PTAP motif. The analysis
identified two important characteristics of subtype C.
The frequency of the sequence duplication and the
length of sequence duplication, both was found signifi-
cantly higher in subtype C as compared to other sub-
types (Fig. 2). Twenty-nine percent of the sequences
(1,474 of 5,074) of subtype C contained the complete
duplication of the PTAP motif (Fig. 2a). A considerably
smaller proportion (380 of 5,901; 6.4%) of subtype B
strains also contained a complete PTAP duplication. In
contrast, only a low frequency of subtype D sequences
(12 of 8,767; 0.1%) contained the PTAP duplication. All
the other HIV subtypes collectively contained less than
5% of sequences characterized by the PTAP duplication.
The BC recombinant HIV-1 strains represented 8% of
sequences containing the PTAP duplication. The HIV-1
groups N, O, and P contained few sequences to permit a
meaningful sequence analysis.
Furthermore, the length of the PTAP motif duplication
was quite heterogeneous with some of the insertions be-
ing as long as 16 amino acid residues. To understand if
the length of the sequence insertion has any association
with the nature of viral subtype, the sequences of sub-
types B and C were compared, as only these two sub-
types contained sufficient numbers. In subtype C, while
Fig. 2 a The relative prevalence of PTAP insertion in HIV-1 subtypes. Full-length gag sequences belonging to the various genetic subtypes of
HIV-1 were downloaded from the LANL HIV sequence database. The subtype identity, total number of gag sequences used in the present analysis
and the number of viral isolates containing the PTAP motif duplication are shown. The percent prevalence of the PTAP motif duplication under
each genetic subtype is depicted. Subtype A represents subtypes A, A1, and A2 and subtype F represents subtypes F, F1, and F2. BC includes 7
different BC recombinants (CRF_07: 8/98, CRF_08: 7/83, CRF_31: 1/3, CRF_60: 0/3, CRF_61: 0/4, CRF_62: 0/3 and CRF_64: 0/6) with PTAP duplication.
Inset: The number and percentage of viral sequences containing insertions of 3 aa or shorter and 12 amino acids or longer are depicted for subtypes B
and C. b The relative prevalence of double-PTAP strains in HIV-1 subtype B and C over the past 30 years. Only those sequences that contained the core
PTAP motif (four amino acids or more) were included in the analysis. Subsets of the full-length gag sequences belonging to HIV-1 subtype B (3,647
sequences) and C (1,787 sequences) were used in the analysis. Only one sequence per subject was included in the analysis. Sequences were categorized
into 5-year periods starting from 1979 (subtype B) or 1986 (subtype C) to 2015. The subtype identity, total number of gag sequences used in the analysis
and the number of viral isolates containing the PTAP motif duplication are shown. The percent prevalence of the PTAP motif duplication under each
genetic subtype is depicted. The increasing trend of PTAP duplication in subtype C was found to be statistically significant (p < 0.05) using the
regression analysis
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7% (357/5,074) of Gag p6 sequences contained PTAP in-
sertions 12–16 amino acids or longer, only 0.39% (20/
5074) of the sequences contained sequence duplication
of three amino acids or less (Fig. 2a). In contrast, in sub-
type B, only 1% of the sequences (52/5,901) contained
PTAP insertions of 12–16 amino acids and as many se-
quences as 11.2% (665/5901) contained insertions of
three amino acid or less. Collectively, the above analysis
is indicative that subtype C has the propensity to intro-
duce PTAP sequence duplications at a higher frequency,
and the duplication length is typically longer.
Additionally, to understand if the prevalence of the
PTAP duplication has been undergoing a variation over
the years, we categorized the full-length gag sequences
of subtypes B and C into 5-year phases starting from
1979 (subtype B) or 1986 (subtype C) up to 2015
(Fig. 2b). In subtype B, the percent prevalence of the
PTAP duplication strains increased between phases
1996–2000 to 2001–2005 from 3.4 to 6.5% and remained
stable after that. A comparable trend was seen in the
context of subtype C but at a higher prevalence. Between
phases 1996–2000 to 2001–2005, the percent prevalence
of the PTAP duplication strains of subtype C increased
from 17.6 to 25% and increased further to 31% preva-
lence in the final phase of 2010–2015 although the sam-
ple size for the last phase is indeed small. Using the
regression analysis to understand the trend, we observed
that the increasing trend of PTAP duplication in subtype
C is statistically significant (p = 0.03) unlike in subtype B
(p = 0.17) where no such trend was seen. Thus, unlike in
subtype B where the prevalence of the PTAP duplication
appears to have been stabilized at the global level, the
prevalence of PTAP duplication appears to be increasing
further in subtype C, which must be confirmed in future
studies.
The length of the PTAP motif duplication varies between
the primary viral isolates but remains constant through
the chronic phase
The sequence analysis performed above confirmed the
global predominance of the PTAP motif duplication in
subtype C Gag sequences. However, the disease status of
the subjects, and their anti-retroviral therapy status and
its influence on the PTAP motif duplication are not
known. Additionally, the profile of the PTAP sequence
duplication and its evolutionary stability has not been
examined in a longitudinal study especially in the con-
text of subtype C infection. To fill this gap, we moni-
tored two different southern Indian clinical cohorts,
consisting of 65 drug-naïve subjects; in a 2 to 3 years
follow-up spanning 2010–2013 with a repeat blood sam-
pling every 6 months. All the subjects belonged to the
chronic stage of the viral infection and were infected
with subtype C reportedly by heterosexual transmission.
The clinical profile of all the 65 study subjects has been
documented (Table 1).
Using a nested PCR, we could successfully determine
the full-length gag sequence from 50 of the 65 subjects
either from the plasma viral RNA or the genomic DNA
extracted from whole blood. In a phylogenetic analysis,
all the primary gag sequences clustered together and
with the reference subtype C viral sequences confirming
their phylogenetic identity (Fig. 3). Of the total 126 gag
sequences generated from the 50 subjects, 100
sequences derived from 42 subjects lacked a sequence
duplication of any kind, thus, representing the wild type
single-PTAP gag profile (Fig. 4). The PTAP elements
consisting approximately of 14 amino acid residues of
the 100 Gag sequences were aligned (Fig. 4). Several of
the sequences contained nucleotide insertions or dele-
tions of variable length including single amino acid vari-
ations in different regions of Gag. In two subjects (T019
and 2010), sequence insertions were found at the N-ter-
minal of Gag p6, but these duplications were not related
to the PTAP motif. The PTAP motif duplication was
found in the remaining eight of the 50 subjects (T004,
T014, 2006, 2012, 2018, 2020, 2032, and 2037). Thirty-
one sequences from the eight subjects were aligned in
the PTAP region consisting of a 14 amino acid window
(Fig. 5). A sequence of 14 amino acids (NRPEPTAP-
PAESFR, the four core residues underlined) representing
subtype C consensus PTAP motif consisting of the four
core residues and the ten flanking residues was used as
references in the multi-sequence alignment. Several im-
portant observations could be made from the sequence
analysis regarding PTAP duplication in the eight sub-
jects. First, the length of sequence duplication was vari-
able in the primary viral isolates. The length of the
original PTAP motif (right side of the dashed line, Fig. 5)
and that of the duplicated PTAP motif (left side of the
dashed line, Fig. 5) both vary in the length of the se-
quences. For a simple representation of these differences
in the PTAP motifs, we use a formula consisting of two
figures. to represent each viral isolate. The right and left-
hand numbers in the formula represent the number of
amino acid residues in the original and duplicated PTAP
motifs in Gag p6 of the viral isolate, respectively. Using
this formula, we found that three of the eight subjects
(T004, 2012, and 2032) contained an original PTAP
motif of 14 residues and a duplication of 14 amino acids
thus representing a configuration of 14 + 14. In contrast,
subjects 2018 contained a PTAP configuration of 12 + 14
representing an original PTAP motif of complete 14
amino acid length but a duplicated PTAP motif shorter
by two amino acids and 2020 contained a PTAP config-
uration of 11 + 14 representing a duplicated PTAP motif
shorter by three amino acids. Subject 2037 contained a
9 + 11 configuration while the other two subjects T014
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and 2006 an 8 + 12 configuration of PTAP duplication.
Second, regardless of the differences constituting the ori-
ginal or duplicated PTAP motifs, in all the subjects at all
the time points, the ‘core PTAP motif ’ is invariably con-
served. Additionally, the aspartic amino acid residue (E)
located immediately upstream of the core motif is also
invariably conserved in the original as well as the dupli-
cated sequences alluding to the functional importance of
these five (EPTAP) residues. Additionally, in an analysis
of sequences downloaded from the extant database also,
we observed that the upstream aspartic amino acid resi-
due is highly conserved. Only 34 of 1,804 (1.8%) subtype
C sequences demonstrated variation at this residue (sin-
gle sequence per subject was included in the analysis,
data not shown). The variations observed between the
original, and the duplicated sequences were exclusively
mapped to the other nine flanking residues of the 14
amino acid motif. The highly preserved ‘EPTAP’ motif is
also seen in the viral strains containing a PTAP motif
duplication of shorter length. Third, in all the viral
strains, the duplicated PTAP motif typically
demonstrates variation at least in one residue as com-
pared to the original PTAP motif. Thus, a sequence vari-
ation between the original and duplicated PTAP motifs
appears more common and necessary. Between the ori-
ginal and the duplicated PTAP motifs, the former is usu-
ally genetically more homologous to subtype C
consensus sequence. Thus, the duplicated PTAP motif
demonstrates a sequence variation of a higher order.
Fourth and importantly, the length of the duplicated
PTAP sequence remained constant at the follow-up time
points in each subject suggesting the stability of the se-
quence length once the motif is duplicated. In subject
T004, for instance, the sequence of the duplicated motifs
remained constant consisting of 14 residues at all the six
different time points spaced 6-month apart (M0, M6,
M12, M18, M24, and M30). Additionally, the duplicated
sequence may undergo further variation in the amino
acid sequence (compare time points M0, M6 and M12
of subject T004. Likewise, different time points of sub-
jects 2032 and 2020), but not in the length of the motif.
This observation suggested that in the chronic phase of
Fig. 3 The phylogenetic analysis of the gag sequences using the neighbor-joining method. Full-length gag sequences (n = 126) derived from 50
subjects were used in the analysis. For two samples (T013-M6p6 and T015-M24p6), only gag p6 could be amplified. Filled circles, filled diamonds
and filled triangles represent the subjects from whom sequences were available at≥ five (n = 6), four (n = 3) and three (n = 13) different time
points, respectively. Open circles represent all the other subjects (n = 28), from whom sequences at less than three time-points were available. The
reference sequences of gag from various genetic subtypes - A, B, C, D, E, F, G, H, J, and K were downloaded from the Los Alamos HIV sequence database.
The star represents subtype C reference sequence. After the gap stripping, there were 1,632 nucleic acid positions in the final dataset. The percentage of
replicate trees in which the associated taxa clustered together in the bootstrap test (1,000 replicates) are shown next to the branches. The tree is drawn to
scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were
computed using the Maximum Composite Likelihood method and were in the units of the number of base substitutions per site
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the viral infection, once the founder viral strains were
established possibly in the acute phase, the length of the
duplications remain stable although the sequence diver-
sity within and between the duplicated and the original
14 amino acids is highly variable. Lastly, at least in two
subjects (2018 and 2014), the presence of the single-
PTAP as wells as double-PTAP viral strains was detected
suggesting a possible mixed infection. Of note, the con-
ventional PCR amplicon sequencing strategy employed
here is limited by the inability to detect minority viral
strains if they are not represented at least at a prevalence
of 20% [31]. Thus, it remains a possibility that other sub-
jects also might contain the single-PTAP viral strains, but
these minority species were not visible in the conventional
sequencing that we employed here. In summary, the PCR
fragment sequence strategy identified that the original
PTAP sequence was relatively conserved among the
subjects, but when any part of the sequence comprising of
the PTAP core motif is duplicated, the amino acid resi-
dues flanking the PTAP core demonstrated a higher mag-
nitude of genetic variation.
In the six study subjects, PTAP duplication was not
associated with the drug-resistance mutations
To find a possible association between PTAP duplication
and drug resistance, primary or transmitted, we determined
the sequences of the pol sequence (Protease, RT, RNase H,
Fig. 4 Multiple sequence alignment of the PTAP region. One hundred
sequences derived from 42 subjects were aligned with the subtype C
consensus (Cons.) amino acid sequence. In the alignment, the dots
represent sequence identity. The PTAP core motifs are highlighted
using the gray shade
Fig. 5 Multiple sequence alignment of the PTAP sequences of eight
primary viral isolates containing PTAP duplication. The sequences
were derived from the plasma viral RNA collected at multiple
longitudinal time-points and by sequencing the PCR fragments. In
three subjects (T004, 2012, 2032), the PTAP motif duplication
involved the duplication of 14 amino acids. In the other five subjects,
the duplicated sequence length was shorter containing 12 (2018),
11(2020), 9 (2037) or 8 (T014, and 2006) residues. Of note, in all the
sequences, the ‘PTAP’ core motif was intact in the original and the
duplicated sequences. Note that in two subjects (2014 and 2018) a
mixed infection of single- and double-PTAP viral strains could be
seen by conventional sequencing. In subject T014, PTAP duplication
was observed only at a single time-point M24. For subject 2006, the
plasma sample was available only at the baseline. The vertical
dashed line demarcates the original and the duplicated PTAP motifs.
The arrows indicate the direction of the RT polymerization. Cons:
The consensus subtype C gag sequence of 14 amino acids. The same
14 amino acid consensus sequence was used twice in the analysis for
convenience. *For these five samples, only gag p6, not the full-length
gag, was amplified. These sequences have not been deposited in the
Genbank and are not part of the phylogenetic tree presented in Fig. 3.
D: the duplicated PTAP motif, O, the original PTAP motif
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and Integrase; coordinates 2,253 to 5,096 as in HXB2) of
the viral strains from all the six subjects of our cohort con-
taining PTAP duplications. We could successfully amplify
the protease from all the six subjects (Accession numbers:
KT124484-KT124490). The RT (Accession numbers:
KT124479-KT124483) and Integrase (Accession num-
bers: KT428977-KT428981) regions could be ampli-
fied from only five subjects. The sequences were
subjected to drug resistance analysis using the HIV
drug resistance database at the Stanford University
(http://hivdb.stanford.edu/). This analysis failed to find
any mutations associated with drug resistance in any
of the viral enzymes in these six subjects. Thus, this
analysis, on the one hand, confirmed the drug-naïve
status of the six subjects and on the other hand,
ruled out ART as a cause for the appearance of PTAP
duplication in these subjects. The immune pressure in
these subjects could be a selection pressure that may
have mediated the PTAP sequence duplication. To
understand if PTAP duplication is associated with the
sequence insertions in other regions of the viral
strains, we determined the sequences of the LTR and
env from the six subjects containing the PTAP dupli-
cation. Env and LTR could be amplified from four
(ascension no: KP683336-KP683342) and five (ascen-
sion no: KP683343- KP683348) of the six subjects, re-
spectively. We did not find any sequence insertions
or other modifications in the V3 loop of the envelope
or the viral promoter (data not shown).
The PTAP sequence duplication in a South-African clinical
cohort
As in India, the viral epidemic in South Africa is
dominated by HIV-1 subtype C. We had access to the
full-length gag sequences of the CAPRISA clinical co-
hort in the city of Durban and rural region of Vulin-
dlela (the Acute Infection Study Team, CAPRISA,
Durban), South Africa. The clinical profile and the
study objectives of the cohort have been reported
previously [32, 33]. The gag sequences of subtype C
origin were derived from 75 subjects, constituting a
subset of the CAPRISA 002 cohort. All the 75 sub-
jects were drug-naïve, in the chronic phase of the in-
fection, and recruited during 2004 to 2010. Access to
the CAPRISA clinical cohort offered an opportunity
to examine the prevalence and evolution of PTAP du-
plication in a different clinical cohort dominated by
subtype C. A total of 150 subtype C p6 gag se-
quences, two from each subject, were available for the
analysis. The first sequence from each subject was
drawn from the acute phase of the infection at the
time of screening or enrollment while the second se-
quence at a later time point eight to 25 months post-
recruitment, representing the chronic phase of the
infection. All the 150 p6 gag sequences were evalu-
ated for sequence insertion of any type in the PTAP
motif region of p6 and aligned with a subtype C con-
sensus sequence generated using the sequences de-
rived from the Los Alamos HIV Sequence Database,
2004 (Fig. 6). The analysis identified sequences of
four different kinds in the 75 subjects depending on
the nature of PTAP duplication. Of the 150 se-
quences, 64% (96/150) did not contain a sequence in-
sertion of any kind in the PTAP motif region thus,
representing the wild type profile. Of the rest of the
54 sequences, four sequences derived from two sub-
jects (CAP008 and CAP224) lacked the duplication of
the PTAP motif but contained an insertion of a se-
quence string located immediately upstream of the
PTAP motif. Of the remainder of the 50 sequences,
42 sequences (28%, 42/150) contained a complete du-
plication of the PTAP core motif (Fig. 7). In the
remaining eight sequences derived from four subjects
(CAP188, CAP248, CAP308, and CAP357), the dupli-
cated PTAP motif was mutated to PTAL, ATAP or
PTTP motifs as also observed in the LANL database.
Each of the mutated motifs differed from the PTAP
motif at a single amino acid residue. It is not known
if such variations are biologically functional. We did
not find such variations in the duplicated PTAP motif
in the Indian clinical cohort of the present study
probably given the small sample size, only eight viral
strains. The insertion length in the 42 sequences con-
taining the complete PTAP duplication ranged from 4
to 16 amino-acids in the South African cohort. Im-
portantly, of the 42 gag p6 sequences derived from 22
subjects that contained a complete PTAP duplication,
in 20 subjects, the duplication was observed at both
the time points of sample collection, at baseline and
the follow-up time point. In two subjects (CAP211
and CAP229), the duplication was found only at the
follow-up time point but not at baseline. Since a con-
ventional Sanger sequencing strategy was used to
examine the viral species in all these samples, it is
not known if the non-detection of the PTAP variant
viral strains at earlier time points from CAP211 and
CAP229 could be ascribed to the limitations in sensi-
tivity. Collectively, the data demonstrated a prevalence
of 29.3% (22 of 75 subjects) PTAP sequence duplica-
tion in the drug-naïve population of the South
African subtype C viral strains, thus, independently
confirming our observations. The present analysis
combined with that of the published reports of sub-
type C collectively ascertains that (1) there is signifi-
cantly higher representation of the PTAP motif
duplication in subtype C as compared to the other
subtypes, (2) the mean length of the PTAP sequence
duplication in subtype C is significantly larger.
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Discussion
Our analysis found that PTAP duplication was signifi-
cantly higher in subtype C compared to other subtypes.
We identified that only a small proportion of global sub-
type B sequences (52/5901, 0.9%) contains a sequence
insertion of 12 amino acids or more leading to the
complete PTAP motif duplication whereas in subtypes A
and D the complete PTAP sequence duplications is ex-
tremely rare. In stark contrast, 29% of the global subtype
C sequences contained insertions leading to complete
PTAP motif sequence duplication (1,474/5,074) (Fig. 2a).
Thus, in subtype C, sequence insertions in PTAP do-
main occur at a higher frequency, most likely even in
the absence of the ART administration which has been
reported to commonly augment the frequency of the
complete duplication of the PTAP motif [22, 28, 34].
The high prevalence of complete duplication of the
PTAP motif in subtype C, especially in drug-naïve sub-
jects, suggests the biological significance of this
phenomenon for subtype C. In this backdrop, through
Fig. 6 Multiple sequence alignment of the PTAP region amino acid residues of the CAPRISA Cohort. One hundred and fifty sequences derived
from 75 subjects were aligned with the subtype C consensus (Cons.) sequence. In the alignment, the dots represent sequence identity and the
dashes sequence deletion. The PTAP core motifs are highlighted in the gray shade. The vertical dashed line demarcates the original (right side)
and the duplicated (left side) PTAP motifs. The consensus subtype C gag sequence of 14 amino acids was used twice in the analysis for convenience
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the present study, we attempted to investigate the fre-
quency of PTAP duplication in subtype C viruses de-
rived from primary clinical isolates of drug-naïve
subjects of India.
The double-PTAP viral strains represented 16% (8/50)
of prevalence in our clinical cohorts. The prevalence of
the PTAP variant strains in three other cohorts of sub-
type C is significantly higher than that of our cohort. In
the well-characterized CAPRISA clinical cohort of the
acute phase infection of subtype C, the PTAP variant
viral strains represent 29.3% (22/75) of the primary in-
fections (Fig. 7) and 30% (212/706) in a South African
clinical cohort [35]. Further, in a cross-sectional analysis
of a Brazilian clinical cohort, the double-PTAP strains
represent 23% (52/228) of the infections in the drug-
naïve subjects and 54% (33/61) in drug-exposed subjects
[28]. The epidemic of India is believed to be younger by
at least a decade as compared to that of the Africa partly
explaining the differences in the frequency of PTAP du-
plication between the two clinical contexts.
Our study also demonstrates that subtype C is
endowed with a superior ability to duplicate longer
stretches of amino acid residues permitting the complete
duplication of the PTAP motif. The length of complete
PTAP duplication in our cohort ranged from 8 to 14
amino acids. Our analysis for the first time showed that
the length of PTAP duplication was highly stable over a
period of 2–3 years of the chronic phase. Thus, it ap-
pears that once a PTAP duplication of a defined length
is acquired, possibly in the early phases of the viral infec-
tion, a variation in the sequence, but not the length, of
the duplicated sequence is permitted at the subsequent
time points. The inferences drawn from the South
African and Indian sequences regarding the length vari-
ation of the PTAP duplication are consistent with each
other.
The data presented here are limited by the sample size
and our inability to draw a correlation between the pres-
ence of double-PTAP viral strains and disease progres-
sion given the lack of information on the plasma viral
load of the subjects and the date of infection. Further,
we also could not perform stringent statistical evalua-
tions on the confounding variables such as the HLA
profile, CD4 counts, and viral load, etc. Nevertheless, all
subjects recruited into the study were drug-naive, be-
lieved to have acquired the virus through heterosexual
transmission, and were free from opportunistic infec-
tions and AIDS-related symptoms. Given these limita-
tions, our results can be considered as inferential
evidence suggesting a positive evolutionary selection of
the variant viral strains in drug-naive subjects. Nonethe-
less, the prevalence of double-PTAPviruses (8/50, 16%)
in drug-naive subjects from two clinical cohorts of India
and in a cohort from South Africa (22/75 subjects,
29.3%, the Acute Infection Study Team, CAPRISA,
Durban) in a longitudinal study, suggests the progressive
expansion of variant viral strains in subtype C. The high
prevalence of the Double-PTAP viral strains in subtype
C has been corroborated by the recent studies from
Brazil [28] and South Africa [35].
Subtype C appears to exploit the phenomenon of se-
quence insertion as a powerful strategy to duplicate
sequence motifs of biological significance to gain replica-
tion advantage. We previously demonstrated that in the
viral promoter, only subtype C viral strains demonstrate
a potential to duplicate the NF-κB binding site while all
the HIV-1 subtypes are capable of duplicating the up-
stream RBEIII binding site including subtype C [4]. The
duplication of the 21 base pairs that constitute the add-
itional NF-κB motif in the viral LTR is highly faithful
without a sequence variation in the duplicated sequence.
The PTAP motif duplication differs from that of NF-κB
motif duplication in being highly variable especially in
the flanking nine residues. Unlike the DNA sequences in
the viral promoter, the amino acid sequences in a viral
protein are prone to immune detection and hence must
undergo rapid variation to evade the immune response.
The selection pressure to avoid immune response per-
haps could explain why the PTAP motifs, the original as
well as the duplicated sequences, are highly variable
when the duplicated NF-κB motif is highly conserved in
subtype C. The NF-κB duplication, and PTAP duplica-
tion in subtype C also differ from each other in another
property. The ability to duplicate the NF-κB motif is an
exclusive property of subtype C, not manifested by other
HIV-1 subtypes [5]. In contrast, both subtypes B and C
can duplicate sequences in the PTAP domain. Thus,
Fig. 7 The pie chart depicts the profile of the sequence insertion in
Gag p6 of the CAPRISA cohort. The 150 gag sequences derived from
75 subjects may be classified into four categories based on the nature
of PTAP duplication; the sequences not containing insertions of any
nature (wild type, 96/150, 64%), variant PTAP duplication (8/150, 5.3%),
non-PTAP insertions 4/150, 2.6%), and complete PTAP duplication 42/
150, 28%). The slices in the pie chart, however, represent the subjects,
not sequences, to avoid confusion regarding the proportion of
complete PTAP duplication between subjects versus sequences. The
proportion of complete PTAP duplication will be 29.3 or 28%
depending on whether the subjects (22 of 75) or sequences
(42 of 150), respectively, are considered
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PTAP duplication is not an exclusive property of subtype
C although subtype C appears to be significantly super-
ior in the ability to duplicate PTAP. Only 0.9% of sub-
type B sequences deposited in the databases contain
PTAP duplication of 12 amino acids, or more whereas
6.6% of subtype C strains contain such large size dupli-
cations (Fig. 2a, inset). The near absence of the complete
PTAP motif duplication in other subtypes, primarily in
A and D for which a large number of sequences are
available in the databases, is quite intriguing. Lastly, the
length of the sequence duplication to constitute the
additional NF-κB motif appears to be fixed, 21 bases,
and invariable in subtype C [5]. In contrast, the se-
quence length of PTAP duplication is highly variable in
both subtypes B and C ranging from 4 to 16 amino acids
[28, 35] (Fig. 5). Because of the complexity of viral qua-
sispecies, we sequenced gag from the genomic DNA
(data not shown) of the selected subjects and observed
the PTAP duplication in the proviral compartment also.
Analysis of sequences from the proviral compartment
will not be the representative of the quasispecies cir-
culating in the plasma, hence it was important to
capture the presence of circulating virions using
plasma viral RNA.
It would be critical to know if the PTAP variant viral
strains are likely to expand in the population in the
coming years like the NF-κB variant viral strains have
been doing currently. At the population level, the rela-
tive success of an emerging variant viral strain primarily
depends on the difference in the plasma viral loads of
the two divergent variant strains, especially in a mixed
infection where the single-PTAP and double-PTAP viral
strains coexist in the same host. It is not known if PTAP
duplication in Gag p6 modulates the infectivity proper-
ties of the envelope in any manner. Especially, in the
context of a mixed infection, the PTAP divergent viral
strains are not likely to differ from each other with re-
spect to the envelope considering the enormous magni-
tude of viral recombination in vivo. The PTAP divergent
viral strains sharing the same envelope, therefore, are
expected to maintain identical biological properties, in-
cluding cell tropism, the preferred route of transmission,
and target cell populations. In a mixed infection, a viral
variant such as the strain containing a double-PTAP
motif represented by a profoundly higher magnitude of
plasma viral load (unpublished data) is likely to be trans-
mitted at a significantly higher rate to the new host. If
this prediction holds true, the PTAP variant viral strains
are expected to expand rapidly replacing the single-
PTAP viral strains in the coming years.
Furthermore, to address the question whether the
PTAP motif duplication is associated with the expansion
of the variant viral strains, we downloaded the available
full-length Gag sequences of subtypes B and C from the
LANL HIV sequence database. Using these sequences
(3,647 and 1,787 representing subtypes B and C, respect-
ively), we asked if the percentage prevalence of the viral
strains containing the duplication increased over the
past 30 years when stratified into 5-year phases starting
from 1979 (Fig. 2b). Given the large sample size, the se-
quences are expected to be representative of the viral
prevalence in the natural infection. In subtype B, the
percent prevalence of the double-PTAP strains doubled
between phases 1996–2000 to 2001–2005 from 3.4 to
6.5% and remained stable after that. A comparable trend
was seen in the context of subtype C but at a higher
prevalence. Between phases 1996–2000 to 2001–2005,
the percent prevalence of the double-PTAP strains of
subtype C increased from 17.6 to 25% and increased fur-
ther to 31% prevalence in the final phase of 2010–2015.
Importantly, a progressively increasing prevalence of the
double-PTAP viral strains was evident in subtype C al-
though the sample size available at the latest phase
2010–2015 is limited (Fig. 2b). Thus, it appears that un-
like in other HIV-1 genetic families, in subtype C alone,
the PTAP duplication appears to be associated with the
global expansion of this HIV-1 subtype. It is necessary
to monitor the expansion rates of the diverse PTAP and
4-κB viral strains in the coming years.
Conclusions
The most significant finding of the present analysis is
that we demonstrated for the first time that the length
of PTAP duplication, but not the sequence within the
duplicated motif, is stable in the chronic phase of HIV-1
infection. We also showed that the frequency of PTAP
duplication is considerably higher in subtype C as com-
pared to other viral subtypes. The subtype C epidemic in
India is believed to be younger by at least a decade as
compared to that of Africa. This difference might partly
explain why the frequency of PTAP duplication is con-
siderably low in India as compared to the African coun-
tries. Using next generation sequencing, we could
identify an absolute domination of the double-PTAP
viral strains over the single-PTAP viral strains, in six of
subjects containing a mixed infection, at several follow-
up time points up to 3 years, in both the proviral DNA
and plasma viral RNA compartments (unpublished data).
Furthermore, using panels of infectious molecular clones
that are genetically similar, we could demonstrate the
domination of double-PTAP viral strain over the single-
PTAP counterpart in the pairwise competition assay.
Since the viral strains competing in the assay differ from
each other only with respect to the presence of an
additional PTAP motif, the replicative domination of the
variant viral clone can be ascribed only to the presence
of the additional PTAP motif (unpublished data). Add-
itionally, using the proximity ligation assay, we could
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show an enhanced association between subtype C Gag
p6 and Tsg101, an important member of the cell endo-
some sorting machinery. Thus, preliminary work from
our laboratory is indicative of the significant replicative
advantage conferred by PTAP motif duplication in sub-
type C. Importantly, unlike in subtype B, the prevalence
of double-PTAP viral strains appears to be increasing in
subtype C. The future studies must monitor the rate of
prevalence of double-PTAP viral strains of subtype C.
The biological significance of PTAP duplication whether
such a variation offers replicative advantage to the vari-
ant viral strains has not been examined. The present
study makes an important finding, offers an explanation
for the replication fitness of the subtype C strains, and
provides many important leads for future research.
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